CLAIMS

What is claimed is:

1. A composition for use in ~~method of~~ treating myopia in an eye of a subject in need thereof, comprising ~~administering a composition that comprises~~ a copper-containing agent selected from: copper perchlorate, copper perbromate, copper periodate, and copper permanganate~~, to an eye of a subject in need thereof~~.

2. The ~~method~~ composition of claim 1, wherein the copper-containing agent is copper perchlorate.

3. The ~~method~~ composition of claim 1 or claim 2, wherein the composition comprises from about 0.001 wt% to about 0.1 wt% of the copper-containing agent.

4. The ~~method~~ composition of any preceding claim, wherein the composition comprises from about 0.005 wt% to about 0.05 wt% of the copper-containing agent.

5. The ~~method~~ composition of any preceding claim, wherein the composition comprises from about 0.01 mg/mL to about 1.0 mg/mL of the copper-containing agent.

6. The ~~method~~ compositionof any preceding claim, wherein the composition comprises from about 0.05 mg/mL to about 0.5 mg/mL of the copper-containing agent.

7. The ~~method~~ composition of any preceding claim, wherein the composition comprises from about 0.05 mg/mL to about 0.25 mg/mL of the copper-containing agent.

8. The ~~method~~ composition of any preceding claim, wherein the composition further comprises an excipient selected from: a tonicity agent, a solubilizing agent, a thickener, a polymer, a buffer, a pH adjuster, a preservative, and water.

9. The ~~method~~ composition of any preceding claim, wherein the composition does not comprise an additional active ingredient.

10. The ~~method~~ composition of any preceding claim, wherein the composition has a tonicity

of from about 200 mOsm/kg to about 600 mOsm/kg.

11. The ~~method~~ composition of any preceding claim, wherein the composition has a pH of from about 5.0 to about 7.8.

12. The ~~method~~ composition of any preceding claim, wherein the composition is administered topically.

13. The ~~method~~ composition of any preceding claim, wherein the composition is an ophthalmic composition.

14. The ~~method~~ composition of any preceding claim, wherein the composition is an ointment, gel, thin film or eye drop composition.

15. The ~~method~~ composition of any one of claims 1-13, wherein the composition is a sustained delivery or depot matrix.

16. The ~~method~~ composition of claim 15, wherein the composition is placed in a cul-de-sac, conjunctiva, subconjunctiva, tenon's capsule or sub-tenon's space, or is placed periorbitally.

17. The ~~method~~ composition of any preceding claim, wherein the composition is delivered by air-gun delivery or ballistic air delivery.

18. The ~~method~~ composition of any preceding claim, wherein the composition is administered at least once per week per eye in need thereof.

19. The ~~method~~ composition of claim 18, wherein the composition is administered at least once per day per eye in need thereof.

20. The ~~method~~ composition of claim 19, wherein the composition is administered at from 1 to 4 time points per day per eye in need thereof.

21. The ~~method~~ composition of claim 19, wherein from about 5 µl to about 100 µl of the composition is administered at each time point.

22. The ~~method~~ composition of any preceding claim, wherein the composition is

administered for a treatment period of at least about 1 week.

23. The ~~method~~ composition of any preceding claim, wherein the composition is administered for a treatment period of at least about 6 weeks.

24. The ~~method~~ composition of any preceding claim, wherein the composition is administered for a treatment period of at least about 6 months.

25. The ~~method~~ composition of any preceding claim, wherein the myopia is progressive myopia.

26. The ~~method~~ composition of any preceding claim, wherein the myopia is non-progressive myopia.

27. The ~~method~~ composition of any preceding claim, wherein the subject is a human having an age of at least about 3 years.

28. The ~~method~~ composition of any preceding claim, wherein the subject is a human having an age of from about 3 years to about 25 years.

29. The ~~method~~ composition of any preceding claim, wherein the subject is a human having an age of at least about 25 years.

30. Use of a copper-containing agent selected from: copper perchlorate, copper perbromate, copper periodate, and copper permanganate in the manufacture of a medicament for treatment of myopia in a subject in need thereof.